A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Conditions:   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia in Remission;   BCR-ABL Positive Chronic Myelogenous Leukemia Interventions:   Drug: Imatinib;   Drug: Nilotinib;   Drug: Dasatinib;   Drug: Bosutinib Sponsor:   National Research Center for Hematology, Russia Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials